Details

Sun Pharmaceutical, India’s largest drugmaker by market value, has agreed to buy Ranbaxy in a $4 billion all-stock deal.

Ranbaxy investors will get 0.8 share in Sun Pharma for every one of their shares. Agam Vakil shares details on the deal valuation and the shareholding pattern. Also, Bloomberg’s Ketaki Gokhale tells you what may happen to Ranbaxy’s U.S. FDA woes post the deal.

This video is originally sourced from Bloomberg TV India, you can watch it here: http://www.btvin.com/videos/watch/6613/Continue-To-Look-For-Deals%3A-Sun-Pharma